Soft tissue sarcoma - historical

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main soft tissue sarcoma page for current regimens.

2 regimens on this page
2 variants on this page


Locally advanced or metastatic disease, combination regimens

Dacarbazine & Doxorubicin

AD: Adriamycin (Doxorubicin) & Dacarbazine

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Baker et al. 1987 (SWOG S7613) 1976-1979 Phase 3 (C) 1. AD & Cyclophosphamide
2. AD & Dactinomycin
Did not meet endpoints of RR/OS
Zalupski et al. 1991 1980-1986 Phase 3 (C) Dacarbazine & Doxorubicin; CI Did not meet primary endpoint of OS50%
Antman et al. 1993 1987-1989 Phase 3 (C) MAID Seems to have superior OS1

1In Antman et al. 1993, although the experimental arm seemed to have superior TTP, this arm seemed to have superior OS.
Here for historic purposes.

Chemotherapy

21-day cycles

References

  1. SWOG S7613: Baker LH, Frank J, Fine G, Balcerzak SP, Stephens RL, Stuckey WJ, Rivkin S, Saiki J, Ward JH. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial: a phase III, Southwest Oncology Group Study (7613). J Clin Oncol. 1987 Jun;5(6):851-61. link to original article PubMed
  2. Zalupski M, Metch B, Balcerzak S, Fletcher WS, Chapman R, Bonnet JD, Weiss GR, Ryan J, Benjamin RS, Baker LH; SWOG. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst. 1991 Jul 3;83(13):926-32. link to original article contains dosing details in abstract PubMed
  3. Antman K, Crowley J, Balcerzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Trump DL, Doroshow JH, Aisner J, Pugh RP, Weiss RB, Cooper BA, Clamond GH, Baker LH. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993 Jul;11(7):1276-85. link to original article PubMed

Doxorubicin & Olaratumab

Regimen

Study Years of enrollment Evidence Comparator Comparative Efficacy
Tap et al. 2016 (CP15-0806) 2010-2013 Randomized Phase 2 (E-RT-esc) Doxorubicin Superior OS
Tap et al. 2020 (ANNOUNCE) 2015-2018 Phase 3 (E-esc) Doxorubicin Did not meet primary endpoint of OS

Chemotherapy

Targeted therapy

21-day cycles

Supportive therapy

References

  1. CP15-0806: Tap WD, Jones RL, Van Tine BA, Chmielowski B, Elias AD, Adkins D, Agulnik M, Cooney MM, Livingston MB, Pennock G, Hameed MR, Shah GD, Qin A, Shahir A, Cronier DM, Ilaria R Jr, Conti I, Cosaert J, Schwartz GK. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016 Jul 30;388(10043):488-97. Epub 2016 Jun 9. Erratum in: Lancet. 2016 Jul 30;388(10043):464. link to original article contains dosing details in manuscript link to PMC article PubMed NCT01185964
  2. ANNOUNCE: Tap WD, Wagner AJ, Schöffski P, Martin-Broto J, Krarup-Hansen A, Ganjoo KN, Yen CC, Abdul Razak AR, Spira A, Kawai A, Le Cesne A, Van Tine BA, Naito Y, Park SH, Fedenko A, Pápai Z, Soldatenkova V, Shahir A, Mo G, Wright J, Jones RL; ANNOUNCE Investigators. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. JAMA. 2020 Apr 7;323(13):1266-1276. link to original article link to PMC article PubMed NCT02451943